Cancer Type: DT/Phase 1

For more information about any of the clinical trials listed on this site, call 314-747-7222 or 800-600-3606 toll free or email Patient_Care_Coordination_Center@bjc.org.

Select Basic Search to view clinical trials grouped by category and Advanced Search to be able to further narrow search results.

 

201407100

A PHASE 1B CLINICAL TRIAL TO EVALUATE THE SAFETY AND IMMUNE RESPONSE TO A MAMMAGLOBIN-A DNA VACCINE IN ER+, HER2- BREAST CANCER PATIENTS UNDERGOING NEOADJUVANT ENDOCRINE THERAPY OR CHEMOTHERAPY

201508140

A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV associated Solid Tumors with Expansion Cohorts in HIV Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma

201510016

A Phase II Study of sEphB4-HSA in Kaposi Sarcoma

201703028

Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors

201711014

A Phase 1, Multicenter, Dose-escalation and Expansion Study of ARX788 as Monotherapy in Advanced Solid Tumors with HER2-expression or Mutation

201807070

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100)

201904006

A multicentre, open-label, non-randomised first in human study of NG-641, an oncolytic transgene expressing adenoviral vector, in patients with epithelial tumours

201904008

A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 in Patients with Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies

201905001

A Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors

201905195

A Phase 1/2 First-in-human Study of BMS-986288 Alone and in Combination with Nivolumab in Advanced Malignant Tumors